Venlighedsvej 1  DK-2970 Hoersholm Denmark  CVR: 28106351 IR@medical-prognosis.com

News:

MPI’s spin-out, Oncology Venture annoncerer overtegning på 370% i forbindelse med aktieemission før IPO på AktieTorget


MPI’s spinout, Oncology Venture announces oversubscription of 370 % of its emission prior to listing at the AktieTorget


Oncology Venture Sweden AB, a spinout from MPI IPOs at AktieTorget


MPI’s drug development arm Oncology Venture raises more than 6 million DKK from private investors


Forløb af ordinær generalforsamling 2015


MPI indkalder til ordinær generalforsamling

Pressemeddelelse

Indkaldelse


MPI publishes Annual Report 2014

Link to Annual Report 2014


MPI’s spin-out Oncology Venture og Lantern Pharma modtager ICIP bevilling til udvikling af Irofulven til metastatisk prostatakræft


Oncology Venture, MPI’s drug development arm and Lantern Pharma receive ICIP grant to advance Irofulven for metastatic prostate cancer


MPI’s DRP-teknologi kan blindet forudsige hvilke patienter med lymfeknudekræft der vil have gavn af standardbehandlingen


MPI’s DPR technology predicts which lymphoma patients (DLBCL) respond to standard treatment (R-CHO(E)P) in a blind setting


MPI’s spin-out Oncology Venture rejser 3,6 mio. kr. til at finde kræftlægemidler som kan reddes af MPI’s teknologi


MPI’s spinout Oncology Venture receives DKK 3,6 million to find anti-cancer drugs to be rescued by MPI’s technology


MPI I temaavis i Berlingske om Bioteknologi

Please click:

http://epaper.infomedia.dk/bioteknologi_29_januar_2015/20150128?s=1&p=10


MPI og Alion Pharmaceuticals Inc  indgår partnerskabsaftale


MPI and Alion Pharmaceuticals, Inc. establish partnership


Forskningsresultater som viser, at MPI’s genetiske responsprofil kan forudsige effekt af adjuverende 5‐FU kemoterapi ved tyktarmskræft, er nu offentliggjort som abstract på ESMO’s hjemmeside


MPI and TD2 Join in Strategic Collaboration to Provide Drug Developers a Unique Multi Biomarker Direct Path to Drug Approval


MPI publishes data showing that MPI's DRP may predict response to fulvestrant

Innovating Prediction

          -Improving Cancer Survival


MPI is an international Biotech/IT company specializing in Precision Medicine by the creation of Biomarkers and development of Companion Diagnostics for the treatment of cancer.

Hør CEO Peter Buhl Jensen fortælle om MPI